Samantha FornerMaidstone and Tunbridge Wells NHS Trust · Department of Oncology
Samantha Forner
MBBS
About
30
Publications
2,732
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
53
Citations
Introduction
Skills and Expertise
Additional affiliations
September 2017 - March 2019
Publications
Publications (30)
BACKGROUND
Molecular glioblastoma (mGBM), without classical histological features, was defined in the 2021 WHO classification based on select criteria (EGFR amplification, TERT promoter mutation (pTERT), chromosome 7+/10-). Subsequent validation relied on retrospective patient re-diagnosis and/or historical histological GBMs (hGBMs) controls. Wheth...
BACKGROUND
Glioblastoma Multiforme (GBM) are aggressive proliferative tumours, which are often large at diagnosis such that radiotherapy unavoidably treats a large percentage of brain. The required expansion margins to create the Planning Target Volume (PTV) for radiotherapy treatment, can often lead to high volumes of normal brain included. In the...
BACKGROUND
GBM patients are associated with a poor prognosis. Hypofractionated radiotherapy (RT) - 40Gy/15# - is standard in the older population (>70), lower performance status and in extensive disease. This regimen provides a median overall survival (mOS) of 8 months and progression free survival (PFS) of 3.9 months (1). The addition of Temozolom...
AIMS:
The 2021 World Health Organisation Classification (WHO CNS5) incorporated molecular diagnostic features for glioblastoma for the first time. The Histo-Mol GBM collaborative is conducting a retrospective cohort study evaluating the outcomes of patients prospectively diagnosed with WHO CNS5 IDH wild type glioblastoma.
METHOD:
Biopsy confirmed g...
AIMS:
The management of older (>70 years old) patients with glioblastoma is challenging with significant variation in practice. Using the Histo-Mol GBM database we analysed the variation in practice across 11 UK centres.
METHOD:
Biopsy confirmed glioblastoma patients diagnosed between 01/01-31/12/2021 were identified. Descriptive statistics were us...
BACKGROUND
A single centre retrospective review of outcomes following linear accelerator - based stereotactic radiosurgery (SRS) for patients with 6 to 18 brain metastases was conducted.
METHODS
Patients receiving SRS to multiple metastatic sites were identified from our institutional database and subsequently stratified into those with 6-9 metast...
AIMS
Brain metastases from gastrointestinal primaries are uncommon with poor reported outcomes following SRS. We evaluated clinical outcomes for patients diagnosed with metastatic brain tumours from a gastrointestinal primary treated with stereotactic radiosurgery (SRS).
METHOD
A single institutional retrospective review of patients treated with L...
Aims
The Covid-19 pandemic expanded the use of virtual consultations (telephone (T) or video (V)). Moving forward, Neuro-Oncology consultation settings require tailoring to optimally meet patient needs. This project aimed to evaluate patient perceptions of consultation settings to optimise service planning and ongoing incorporation of T and V optio...
Patients with Glioblastoma Multiforme (GBM) have a poor prognosis with few long-term survivors (>2 years from diagnosis). This review analyses key characteristics of this cohort.
METHODS: Retrospective single-centre review of GBM patients treated with the STUPP protocol at a Regional Neuro-oncology centre, Nov-09–Sept-19. Demographics, histology...
INTRODUCTION
Stereotactic radiosurgery (SRS) commenced at Guy’s Cancer Hospital in August 2017. We report our first seventeen months’ data (August 2017 to December 2018) for brain metastases SRS.
METHOD
Patients referred via Neuro Oncology MDT were assessed for suitability for SRS via clinical review and 1mm-slice MRI. Treatment was planned on Ecl...
Introduction: Dual HER2 targeting improved pCR rates (ypT0ypN0) compared with Herceptin plus chemotherapy in the TRYPHAENA and NeoSphere registration trials. Pertuzumab-containing regimens (FEC-THP and TCHP) were adopted at the Kent Oncology Centre (KOC) following national funding approval in December 2016.
Methods: A retrospective study of 176 (st...
Objective
Correct labeling of twin fetuses is needed for consistency in assigning and interpreting longitudinal scan and prenatal screening/diagnostic results. The aim of this study was to describe a standard method of twin labeling in the first trimester of pregnancy and to assess the robustness of such a technique in predicting the presenting twi...
Correct labeling of twin fetuses is needed for consistency in assigning and interpreting longitudinal scan and prenatal screening/diagnostic results. The aim of this study was to describe a standard method of twin labeling in the first trimester of pregnancy and to assess the robustness of such a technique in predicting the presenting twin in subse...